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Purpose: The value of patients as potential reporters into pharmacovigilance systems is acknowledged 
worldwide and allowed in Thailand. +RZHYHU QRWKLQJ LV NQRZQDERXW WKH7KDL SXEOLF¶V DZDUHQHVVRI GLUHFW
patient reporting facility or their views concerning it. This study aimed to determine confidence among 
members of the public in identifying suspected ADRs, information sources they use and their views towards 
direct ADR reporting. 
Methods: Mixed methods study consisting of self-administered questionnaires (phase 1) and semi-structured, 
face-to-face interviews (phase 2) with members of the public, recruited in primary care centres, pharmacies and 
public places during October 2013 to February 2015. All questionnaire respondents reporting an ADR were 
invited to participate in Phase 2. Written informed consent was made before the start of the interview.   
Results: There were 414 (17.2%) of 2400 questionnaire respondents who had experienced an ADR, almost half 
(46%) of whom used their own experience to identify ADRs. Having a degree, having a severe ADR and 
consulting a physician increased respondent confidence in the association between medicine and suspected 
ADR. The majority (27) of the 30 interviewees indicated general agreement with patient reporting to regulatory 
authorities. Four main themes emerged covering reasons for reporting ADRs including expectations of health 
authorities, healthcare professionals and manufacturers, and helping other people. Awareness of direct reporting 
was low with a desire for a range of reporting methods.  
Conclusion: Results indicate support among the Thai general public of direct ADR reporting. Greater promotion 
of direct reporting by all healthcare professionals is required. 
 




 Spontaneous reporting is a fundamental drug safety monitoring process, the effectiveness of which is 
dependent on voluntary reporting, mainly by healthcare professionals, but which is limited by under-reporting 
and report quality [1-2]. The potential value of patients as potential reporters into pharmacovigilance systems is 
increasingly acknowledged worldwide. Direct patient reporting to regulatory authorities is viewed as important 
and a large numbers of countries now permit and encourage patients to report ADRs [3-4]. Patient reporting 
may enable earlier detection of unexpected ADRs and increase the overall rate of spontaneous reporting. 
Previous studies have shown that healthcare professionals and patients report a similar proportion of ADR in 
term of seriousness and that the quality of information reported by patients was good. Moreover, many studies 
suggested that patient reporting provides a range of benefits and their reports tend to provide more detailed 
descriptions of their experiences than those of healthcare professionals [5-7]. 
 In Thailand, the Health Product Vigilance Centre (HPVC) is the authority responsible for drug safety, 
to which patients have been allowed to submit online reports of suspected ADRs since 2010 but the number of 
reports received is very limited. However, nothing is known about the public¶V awareness of this reporting 
facility or their views concerning it. Several studies elsewhere have shown the need for greater publicity 
regarding direct patient reporting and a need for multiple reporting methods to be available [5, 8-9]. Patients use 
a variety of means to help them identify suspected ADRs. In countries where patient information leaflets are 
widespread, such as the UK, these play an important role in ADR identification, which then facilitates direct 
reporting [5]. However in Thailand, these leaflets are not routinely available with medicines and a previous 
qualitative study found that Thai patients rely more on health professionals to identify suspected ADRs [10].  
Greater understanding is needed about the methods by which Thai patients identify suspected ADRs, plus their 
views on reporting these. Such understanding could help to improve both the rate and the quality of patient ADR 
reporting. Our previous study focused on the frequency and characteristic of ADRs, views of Thai people 
towards ADR information and ADR knowledge [14].  This study subsequently aimed to determine experiences 
of members of the public who had had a suspected ADR on the information sources and other means used to 
help identify the suspected ADR, factors affecting their confidence in the association and their views towards 
direct ADR reporting. 
 
2 Methods  
2.1 Study design and study sample 
 The study was approved by the Khon Kaen University Ethics Committee for Human Research in 
accordance with the Declaration of Helsinki and the International Conference on Harmonization for Good 
Clinical Practice (Institutional Review Board Number: IRB00001189). It was a two phase, mixed methods study 
and was conducted in Khon Kaen province, the second-largest of the north-eastern provinces of Thailand, 
during October 2013 to February 2015.  
2.1.1 Phase 1 
 This phase involved a self-administered questionnaire designed to determine experiences of the general 
public with regard to ADRs, which was developed using previous literature [5, 11-13]. Full details of the 
questionnaire are described elsewhere, together with overall results [14].  
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 Here we present data from study respondents who indicated they had experienced a suspected ADR. In 
addition to questions relating to the ADR experience itself, the questionnaire included three further questions: (i) 
information sources used to help determine the association between a symptom and suspect drug; (ii) other 
factors which helped them to make the association, using options derived from previous work [10]; and (iii) 
confidence about the association, using five levels (lowest, low, medium, high, highest). 
 The final questionnaires were directly distributed by hand to participants who were aged over 18 years, 
by convenience sampling at three main types of locations: four primary care units (PCU), four community 
pharmacies and three public areas, with a total target sample size of 2400. After distribution, the researchers left 
the area to give recipients time to decide to participate and allow sufficient time to complete the questionnaires 
themselves before they were collected.  Further details are published elsewhere [14]. Once completed 
questionnaires were returned, all Phase 1 respondents who reported they had experienced an ADR and 
completed all relevant sections of the questionnaire, were verbally invited to participate in Phase 2 and to 
provide their contact details. All respondents who were willing to participate in the interview and gave contact 
information were included. 
 
2.1.2 Phase 2 
 This phase consisted of a semi-structured, face-to-face interview to explore further how participants 
identified their unexpected symptoms as an ADR and their views towards ADR reporting. Phase 1 respondents 
were telephoned to make an appointment for interview. Written informed consent was obtained from all 
participants before the start of the interview.  During interviews, which were all performed by AP aiming for a 
duration of between 30 to 45 minutes, open questions were asked based on the interview schedule as a standard 
guideline, and all were audio-recorded. The interview guideline was developed by the research team, based on 
previous literature [10] and covered: identification and evaluation of the suspected ADR (sources used, factors 
considered) and their attitudes towards reporting ADRs (experiences and expectations about reporting to health 
professionals and authorities).  
 
2.2 Data analysis 
2.2.1 Phase 1  
 All valid data retrieved from the returned questionnaires were analyzed using IBM SPSS for Windows 
version 19.0 (IBM Corp., Armonk, N.Y.). 5HVSRQGHQWV¶ confidence in ADR identification was reported using 
descriptive statistics, then confidence was dichotomized into medium/low/lowest and high/highest. 
Relationships between variables were analyzed using Pearson Chi-VTXDUHȤWHVW/RJLVWLFUHJUHVVLRQZDVXVHG
to determine factors associated with degrees of certainty. Differences with p-values less than 0.05 were regarded 
as statistically significant.  
 
2.2.2 Phase 2 
 All interviews were transcribed into Thai. The transcripts were translated into English by AP and all 
were checked independently by NJ, for accuracy.  Interview data were analyzed using thematic analysis. The 
interview transcripts were first read and coded manually by AP and the analysis was checked and reviewed by 
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NJ. Discussions took place between these two researchers which enabled codes to be categorized into major 
themes and for new codes to emerge. The codes and themes from the second analysis were discussed and 
reviewed again by all researchers and final themes agreed.     
 
3 Results 
 There were 2935 people invited to participate, of these 2450 accepted a questionnaire and 2400 
returned a valid questionnaire. Demographic details of the study participants are shown in Table 1. of the 2400 
respondents, 414 (17.2%) indicated they had experienced an ADR. The majority of these respondents were 
female (66.4%; n=275) and the average age was 38.1± 15.6 years (range from 18 to 79 years). A half were 
graduates with a bachelor degree or higher (50.2%; n=208). There were 170 (41.1%) of respondents who 
claimed to have an underlying chronic disease. 
[Insert Table 1 here] 
 
3.1 Phase 1 Questionnaire findings 
 Two-thirds (276; 66.7%) of questionnaire respondents had experienced mild symptoms, 105 (25.4%) 
moderate and 33 (8.0%) severe symptoms. Over half (230; 55.0%) indicated their experience was within the last 
year. The information sources used by respondents to help in identifying ADRs are shown in Table 2, with 
personal experiences and health professionals being the most commonly cited. Table 3 shows the individual 
means by which respondents made the association between the symptoms and suspected drugs. The reason most 
frequently selected was that the ADRs occurred after the drugs were taken (350; 53.4%), with other frequently 
cited reasons being: no co-medication being taken concurrently (90; 13.7%), ADRs occurred after the drugs 
were taken again (89; 13.6%), and they had experienced ADRs from this drug before (48; 7.3%). 
[Insert Table 2 here] 
[Insert Table 3 here] 
 In response to question (iii), over half the respondents felt that their level of confidence in the 
experience being an ADR was high (120; 29.0%) or highest (90; 22.9%). A further 124 (30.0%) had a moderate 
level of confidence and less than a fifth had little confidence in the association between suspected ADR and 
medicine: n=39 (9.4%) low level and n=36 (8.7%) lowest level. 
Factors potentially related to UHVSRQGHQWV¶FRQILGHQFHLQWKHDVVRFLDWLRQEHWZHHQWKHV\PSWRPDQGWKH
drug were initially analyzed by Pearson chi-square. Univariate analysis showed that respondents with higher 
education level (p=0.001), working for the state or in business (p=0.006), having higher income (0.011), 
increasing severity of ADR (p<0.001) and whether or not they had consulted a physician (p<0.003) were 
significantly associated with higher confidence in ADR identification (Table 4). Table 5 shows the results of 
logistic regression analysis, which indicates that higher educational level was the most significant factor in 
increasing confidence in the association (OR 2.412; 95%CI 1.589, 3.662; p<0.001). In addition, a clear trends 
was visible in confidence level with increasing ADR severity and consulting a physician was also associated 
with high confidence.   
[Insert Table 4 here] 
[Insert Table 5 here] 
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3.2 Phase 2 Semi-structured interviews 
 A total of 64 Phase 1 participants (15.5%) provided contact details and indicated a willingness to 
participate in semi-structured interviews, and 30 (47%) interviews were conducted. Of the remaining 34 people, 
20 subsequently refused to be interviewed and 14 could not be contacted by phone. The mean duration of the 
interviews was 27.8±7.6 minutes.  Interviewees differed slightly from Phase 1 respondents in that more were 
female, they were older, more were graduates with a bachelor degree and more had underlying chronic disease 
(Table 1). However they were similar in terms of the severity of their ADR experiences.  
 
3.2.1 How ADRs were identified 
 All interviewees provided at least one explanation regarding the processes that they used to identify 
their unusual symptom as an ADR. Two main themes emerged, covering factors related to medicine use and 
information sources. 
 
Factors related to medicines use   
 The identification process mentioned most frequently, indeed by all participants, was the timing 
relationship, most of whom indicated that symptoms occurred after they took the suspected medicines. Others 
mentioned that symptoms had never occurred before and that symptoms disappeared after they discontinued the 
suspected medicines. Some could relate their unusual symptoms to suspected medicines because it was their 
first time of taking these medicines. 
³,GLGQRWGLVFRQWLQXHPHGLFLQHLPPHGLDWHO\,FRQWLQXDOO\WRRNLWIRUWRGD\VEHFDXVH,GLG
not believe that symptoms were caused from this medicine that I took, until I stopped taking the 
VXVSHFWHGPHGLFLQHDQGV\PSWRPVGLVDSSHDUHG´ (Female, 39, Doctoral Degree, no U/D) 
 Interview data provided more detail about how people supported the identification of ADRs through 
other means, such as consideration of the possibility of alternative causes, changes in the symptom relating to 
the dose taken and previous experiences with similar drugs. For example: 
³,WGLGQRWUHODWH WRFKURQLFXQGHUO\LQJGLVHDVHEHFDXVH,H[SHULHQFHG WKHGLVHDVH IRUPDQ\
years and the symptoms had never occurred before. If the symptoms were related to the disease, the 
V\PSWRPVZRXOGEHRFFXUULQJVLQFHPDQ\\HDUVDJR´ (Female, 27, Bachelor degree, no U/D) 
  ³,KDGLQFUHDVHGDQGGHFUHDVHGthe dose of my suspected medicine. Symptom was decreased 
 when I reduced the dose, and the symptom was getting worse when I incrHDVHGWKHGRVH´(Female, 53, 
Diploma, U/D) 
 Interestingly, there were nine participants took the suspected medicine again after the 
symptom was disappeared. Three of these were re-challenged with the suspected medicine because 
either they or healthcare professionals were not aware of the previous ADR and thus unable to prevent 
recurrence. ³,IRUJRWWRWHOOSK\VLFLDQWKDW,KDGKLVWRU\RIGUXJDOOHUJ\6XUSULVLQJO\,ZDVSUHVFULEHG
Penicillin again and I took it. So, the symptoms occurred and then I hurried to take anti-histamine and 
WKHV\PSWRPVZHUHUHOLHYHG´ (Male, 71, Bachelor degree, U/D) 
Some subjected themselves to re-challenge with the suspected medicine in order to confirm their 
suspicion of the ADR. 
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³I was not sure that whether I was allergic to Biocalm or not. So I tried to take it again for 
muscle relaxation. The symptoms occurred as I had previously experienced after I took it. Then, I took 
anti-KLVWDPLQHDQGWKHV\PSWRPVZHUHUHOLHYHGZLWKLQDQKRXU´ (Male, 62, Master degree, U/D)   
 
Information sources  
 Other ways in which participants assessed unusual symptom as an ADR involved their use of 
information sources, together with their personal beliefs about their medicine. Over half the participants said 
they used information sources to confirm their identification. The information was directly provided by 
healthcare professionals in 11 participants, but six obtained information from non-healthcare professionals, 
including friends and the internet, as well as using their own knowledge. 
   ³,GLGQRWWKLQNWKDWP\V\PSWRPVUHODWHGWRRWKHUPHGLFLQHVEHFDXVHSK\VLFLDQWROGPHWKDW
 you were allergic to Sulfa drug. So, I was confident WKDW,ZDVDOOHUJLFWR6XOIDGUXJ´ (Male,  70, 
Master degree, U/D) 
 Personal beliefs UHODWHGWRSHUFHSWLRQVDERXWWKHVWUHQJWKRIPHGLFLQHVDGPLQLVWUDWLRQDQGWKHLUERG\¶V
ability to accept medicines. 
  ³, WKRXJht that unusual symptoms occurred because I was prescribed too high a dose of 
 medicine and I [only] took a little bit of water. Therefore, I would receive a concentrated dose of 
 PHGLFLQH´ (Female, 25, Bachelor degree, U/D) 
 
3.2.2 Attitudes towards direct reporting of ADRs 
 Two main themes emerged concerning attitudes towards patient reporting to regulatory authorities, 
with the majority indicating general agreement with this, as well as providing opinions on methods of ADR 
reporting.  
  ³,t is good because it would reduce workload of medical staff. Furthermore, patients are best 
 understanding of their health status than other person. Hence, to allow patients to report ADRs by 
 themselves iVJRRG´  (Case 030, Male, 25, Bachelor  degree, U/D) 
 Only a few disagreed with patient reporting, with reasons given being because they perceived that 
reporting ADRs was unimportant, the reported data may be incorrect and the difficulty of reporting. The 
majority considered it was appropriate for patients to report directly themselves, but some considered that 
reporting should go through health professionals. 
 
 Regarding the method of ADR reporting, preferred methods were varied, including internet, email, 
Facebook, telephone, call center and post.  
³5HSRUW$'5VYLDLQWHUQHWLVWKHEHVWEHFDXVHQRZDGD\VHYHU\ERG\KDVRZQVPDUWSKRQHDQG
WKH\FRXOGDFFHVVWKURXJKWKHLQWHUQHWE\WKHPVHOYHV´ (Female, 22, Bachelor degree, no U/D)  
 Several commented that they would need feedback after reporting or felt they should be able to discuss 
the suspected ADR with someone, which influenced their suggestions for the ideal reporting method.  
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³7KH\VKRXOGVHWXS WHOHSKRQHRU LQWHUQHWDQGKDYHDYDLODEOH VWDII WRDQVZHUDQ\TXHVWLRQV
immediately, because the person who experienced unusual symptoms would feel anxiety with their 
V\PSWRPV´ (Female, 27, Bachelor degree, no U/D) 
 
3.2.3 Expectations about reporting of ADRs 
 Four themes were evident from the interviews covering reasons why people may want to report ADRs 
and their expectations regarding reporting. These were: expectations of health authorities, healthcare 
professionals and manufacturers, and helping other people. 
 
Expectations of health authorities 
 More than half the participants expressed views concerning health authorities, some of which included 
their need for more information, as well as responses when they reported an ADR. Most participants felt that 
they lacked knowledge and desired more. Others mentioned that the authorities needed to affirm safety and 
quality of marketed and prescribed drugs after they reported an ADR. 
³,would want to receive information about how to manage ADRs after I reported an ADR. 
Moreover the authorities should affirm manufacturing processes of medicine if there are many people 
H[SHULHQFHGDQ$'5´(, Female, 22, Bachelor degree, no U/D) 
Some participants stated that no one knew about patient reporting via Thai HPVC. They viewed it as a 
task of health authorities to promote how this worked and how to access this system, illustrated by the following 
statement: 
  ³7KH 7KDL FDA should advertise about direct reporting to the public such as this website 
 (Thai HPVC) because nobody knew about this method and they did not  know the way to report their 
 V\PSWRPV´ (Female, 22, Bachelor degree, no U/D) 
 
Expectations of manufacturers  
 Most participants expressed the hope that medicines should be improved, and that leaflets or brochures 
may be more widely available and the reported ADRs should be added into these leaflets.  ³7KH GUXJ
company should create short leaflet for patients when their medicines are  GLVSHQVHG´ (Female, 20, 
Bachelor degree, no U/D) 
   
Expectations of healthcare professionals  
 Some participants expressed views that they wanted to inform healthcare professionals about ADRs 
because they desired healthcare professionals to monitor and manage their unusual symptoms.  
³, would need home visit and close monitoring from healthcare professionals to prevent 
UHFXUUHQWRIXQXVXDOV\PSWRPV´ (Male, 71, Bachelor degree, U/D) 
 
To help other people 
 Many interviews described altruistic views, demonstrating the desire to share their experiences and to 
make other people aware of ADRs. 
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³, would not require any acknowledgement « RQO\ WKH ZRUG ³WKDQN \RX´ IURP WKH
 authorities. I think that it could be useful to other person. If there were many people allergic to this 
 medicine, Thai FDA should be concerned about safety information of medicines or withdraw the 
 VXVSHFWHGPHGLFLQHLISRVVLEOH´ (Female, 37, Doctoral degree, U/D) 
 
4 Discussion 
4.1 Main findings 
 This study showed that among Thai people who had experienced a suspected ADR, those with higher 
educational levels, more severe symptoms and those who had discussed their experience with a health 
professional had greater confidence in the association. All questionnaire respondents were able to provide at 
least one reason that they suspected a causal relationship between the suspected ADR and a drug. Almost half 
drew on personal experiences, with over a third confirming their causality assessment with healthcare 
professionals. The latter figure is higher than was found in studies from both the UK [15] and Japan [16]. Other 
information sources, such as medicine leaflets and the Internet, were used relatively infrequently, similar to 
these other studies [15-16].  
 Timing relationships was the most common basis on which suspected ADRs were identified, which is 
also in line with other studies [10, 15-17]. The qualitative data confirmed that people tended to try to eliminate 
other potentially causative factors and many used their experiences of re-challenge to evaluate their symptoms. 
Studies in both the UK and the US have proposed that patients could identify their ADRs related to the 
suspected medicines based on both timing issues and their own knowledge [18-19]. Our study also confirmed 
WKLVZLWKVRPHEHLQJDZDUHRILQGLYLGXDOGUXJV¶SRWHQWLDOIRUFDXVLQJ$'5VHowever beliefs about medicines 
DOVRLQIOXHQFHGVRPHLQGLYLGXDOV¶YLHZVRQWKHDVVRFLDWLRQ 
 While the Thai HPVC has allowed the public to directly report unexpected symptoms related to 
medicine and health products since 2010, this is the first study to explore public views on and awareness of this 
system. It found that most of the interview participants were in favour of direct reporting as contributing to 
pharmacovigilance in Thailand. However a minority felt that in order to confirm causality assessment of their 
ADRs, patients should report ADR to healthcare professionals first. A similar view was expressed by some 
patients in a qualitative UK study [20] who considered that ADR reporting was a task for health professionals 
and not their responsibility, whereas the prevailing concern in our study was the quality of reports and certainty 
of the association. Altruistic reasons were mentioned by most interviewees, with only a minority expressing the 
view that it was an opportunity for personal gain, which is in line with other studies in UK and the Netherlands 
[13, 21-23]. Patient reporters in the UK considered that reporting was important for both manufacturers and 
authorities, leading to potential improvements in medicines, as well as amendments to information leaflets and 
withdrawal of medicines if necessary [13], which was also found in the present study. The personal benefits 
sought were more information about medicines, confirmation about suspected ADRs and management of their 
ADR, which again is in line with previous work [22]. Other participants were not desirous of receiving 
feedback.  
These previous studies have involved people who had reported suspected ADRs to regulatory 
authorities, in countries where provision of a patient information leaflet with all supplied medicines is a legal 
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requirement. Our study involved members of the public, none of whom had reported, in a country where patient 
information leaflets are scarce [24]. It is therefore interesting that some interview participants had an 
understanding of the potential implications of reporting ADRs for medicines leaflets. Indeed some suggested 
that such leaflets should be provided with all medicines and include the ADRs reported by the public. There was 
however a lack of awareness of the reporting process, and suggestions for greater publicity and alternative 
reporting options were offered.  
 
4.2 Strengths and limitations 
 This mixed method study targeted the community-dwelling public with experiences of suspected 
ADRs, as potential contributors to direct reporting in Thailand. The study was conducted in only one area of 
Thailand, but involved multiple recruitment methods in order to reach a diverse population. Studies elsewhere 
have used street survey or telephone survey to obtain views and experiences of the public on direct ADR 
reporting, while many studies exploring how people identify ADRs have involved people who have already 
reported their experience to regulatory authorities. Self-completed questionnaires were used to determine 
confidence in identifying ADRs, enabling factors affecting confidence in this to be studied. Interviews then 
enabled participants to explain their experiences and provide opinions on direct reporting individually in their 
own words.  
 
5 Conclusion 
 The findings suggest that the general public in Thailand use mainly their own experience and 
information from health professionals to identify suspected ADRs. They are not aware of the facility to report 
ADRs directly, but are willing to share their experiences of suspected ADRs with the Thai regulatory authority, 
to improve medicines safety. Greater promotion is required of direct reporting, by all stakeholders, including the 
Thai FDA, as well as individual physicians, pharmacists and nurses.  
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Table 1 Demographic details of study participants  












Age (year)  
 <45 
  












Education Level  
 Secondary school and lower 







Major career  
 Not working 
 Student  
 Farmer / manual worker 
 Government official and state enterprise employee  













































Table 2 Information sources used to identify ADRs (N=414) 
Sources of information Total N (%) 
Own experiences 191 (46.1) 
Healthcare professionals 158 (35.8) 
Information leaflets 64 (15.5) 
Relatives 63 (15.2) 
Internet  45 (10.9) 




Table 3 Factors involved in ADR identification 
Reasons Total N (%) 
 ADRs occurred after the drugs were taken 
 No co-medication was taken when ADRs experienced 
 ADRs occurred after the drugs were taken again  
 Had experienced ADRs from this drug before  
 Symptoms of an underlying disease were not similar to the ADR 
symptoms 
 Other people who took similar drugs have experienced the same 
ADRs 
 Physical and/or blood examination were abnormal after the drugs 
were taken 















Table 4 Univariate analysis of factors related to levels of ADR identification (N=414) 
Characteristic 
                            
Levels of confidence 
No. of individuals (%)  




















Age (year)  












Education Level  
 Secondary school and lower 











Major career  
 Not working/student  
 Farmer/manual worker 

























































When ADRs occurred 
 Within 1 month ago 
 Within 6 months to 1 year ago 















 1 - 3days 
 4 - 6days 
 1 - 4weeks 
 1 - 3months 
































































 Pearson Chi-Square test 
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Table 5 Logistic regression analysis of factors associated to levels of certainty in ADR identification  
Variables 
No. of individual (%)  Adjusted 
OR 
95% C.I. 
p-valuea Low to 
moderate High Lower Upper 
Education Level  
 Secondary school 
and lower 












































































 The association between variables was analyzed by Logistic regression 
